Voors-Pette C - Search Results

1

Influence of Rifampin-Mediated Organic Anion-Transporting Polypeptide 1B1/1B3 Inhibition on the Pharmacokinetics of Clazosentan.

Juif PE, Voors-Pette C, Ufer M, Dogterom P, Dingemanse J. Juif PE, et al. Clin Transl Sci. 2019 Sep;12(5):440-444. doi: 10.1111/cts.12639. Epub 2019 May 6. Clin Transl Sci. 2019. PMID: 31004470 Free PMC article. Clinical Trial.

2

Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab.

Voors-Pette C, Lebozec K, Dogterom P, Jullien L, Billiald P, Ferlan P, Renaud L, Favre-Bulle O, Avenard G, Machacek M, Plétan Y, Jandrot-Perrus M. Voors-Pette C, et al. Arterioscler Thromb Vasc Biol. 2019 May;39(5):956-964. doi: 10.1161/ATVBAHA.118.312314. Arterioscler Thromb Vasc Biol. 2019. PMID: 31017822 Free article. Clinical Trial.

3

Effect of Rifampin-Mediated OATP1B1 and OATP1B3 Transporter Inhibition on the Pharmacokinetics of the P2Y12 Receptor Antagonist Selatogrel.

Schilling U, Dingemanse J, Voors-Pette C, Romeijn C, Dogterom P, Ufer M. Schilling U, et al. Clin Transl Sci. 2020 Sep;13(5):886-890. doi: 10.1111/cts.12774. Epub 2020 Mar 31. Clin Transl Sci. 2020. PMID: 32166864 Free PMC article. Clinical Trial.

4

Population Pharmacokinetic/Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen-Induced Platelet Aggregation.

Renaud L, Lebozec K, Voors-Pette C, Dogterom P, Billiald P, Jandrot Perrus M, Pletan Y, Machacek M. Renaud L, et al. Among authors: voors pette c. J Clin Pharmacol. 2020 Sep;60(9):1198-1208. doi: 10.1002/jcph.1616. Epub 2020 Jun 4. J Clin Pharmacol. 2020. PMID: 32500636 Free PMC article.

5

Association Between Vomiting and QT Hysteresis: Data from a TQT Study with the Endothelin A Receptor Antagonist Clazosentan.

Juif PE, Dingemanse J, Voors-Pette C, Ufer M. Juif PE, et al. Among authors: voors pette c. AAPS J. 2020 Aug 3;22(5):103. doi: 10.1208/s12248-020-00485-6. AAPS J. 2020. PMID: 32748293 Clinical Trial.

6

The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects.

Mueller MS, Sidharta PN, Voors-Pette C, Darpo B, Xue H, Dingemanse J. Mueller MS, et al. Among authors: voors pette c. Orphanet J Rare Dis. 2020 Oct 27;15(1):303. doi: 10.1186/s13023-020-01582-7. Orphanet J Rare Dis. 2020. PMID: 33109218 Free PMC article. Clinical Trial.

7

Pharmacokinetics, pharmacodynamics and safety of the novel C-X-C chemokine receptor 3 antagonist ACT-777991: Results from the first-in-human study in healthy adults.

Boof ML, Géhin M, Voors-Pette C, Hsin CH, Sippel V, Strasser DS, Dingemanse J. Boof ML, et al. Among authors: voors pette c. Br J Clin Pharmacol. 2024 Feb;90(2):588-599. doi: 10.1111/bcp.15914. Epub 2023 Nov 16. Br J Clin Pharmacol. 2024. PMID: 37752659 Clinical Trial.

8

First-in-Man Safety, Tolerability, and Pharmacokinetics of a Novel and Highly Selective Inhibitor of Matrix Metalloproteinase-12, FP-025: Results from Two Randomized Studies in Healthy Subjects.

Abd-Elaziz K, Voors-Pette C, Wang KL, Pan S, Lee Y, Mao J, Li Y, Chien B, Lau D, Diamant Z. Abd-Elaziz K, et al. Among authors: voors pette c. Clin Drug Investig. 2021 Jan;41(1):65-76. doi: 10.1007/s40261-020-00981-9. Epub 2020 Dec 17. Clin Drug Investig. 2021. PMID: 33331980 Clinical Trial.

9

Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG.

Verma S, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Dhingra NK, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Mason RP, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Verma S, et al. Circulation. 2021 Dec 7;144(23):1845-1855. doi: 10.1161/CIRCULATIONAHA.121.056290. Epub 2021 Oct 28. Circulation. 2021. PMID: 34710343 Free article. Clinical Trial.

10

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.

Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, Shih WJ, Gantz I, Terra SG, Cherney DZI, McGuire DK; VERTIS CV Investigators. Cannon CP, et al. N Engl J Med. 2020 Oct 8;383(15):1425-1435. doi: 10.1056/NEJMoa2004967. Epub 2020 Sep 23. N Engl J Med. 2020. PMID: 32966714 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

23 results

Search Page